2020-10-12 09:20:11 GILD Gilead
Galapagos
10/12/20 10/1209:20 10/12/2009:20 | Gilead, Galapagos presents data from Phase 2b/3 trial of filgotinibGilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly higher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented today at the 2020 United European Gastroenterology Week Virtual Meeting. UC is a longer-term condition characterized by inflammation of the mucosal lining of the colon and rectum. An increasingly prevalent disease, UC has a significant impact on the quality of life of more than 2 million people around the world. Despite current treatments, many patients experience fecal urgency, incontinence, recurring bloody diarrhea, and the need to empty their bowels frequently, often accompanied by abdominal pain, poor sleep and fatigue. The SELECTION study included biologic-naive patients, for whom prior conventional therapy had failed, as well as biologic-experienced patients, a high proportion of whom had been non-responders to at least two different lines of prior biologics. In total, 43 percent of patients in the biologic-experienced cohort had failed treatment with both a TNF inhibitor and vedolizumab. The study allowed the enrollment of patients who were taking steroids, and/or immunomodulators, including methotrexate, mercaptopurine or azathioprine, as they would in real-world clinical practice. Overall, 1,348 biologic-naive or biologic-experienced adult patients with moderately to severely active UC were randomized and treated in the SELECTION study. Among biologic-naive patients treated with filgotinib 200 mg, a significantly higher proportion of patients achieved clinical remission at Week 10 compared with placebo. Additionally, a significantly higher proportion of biologic-naive patients treated with filgotinib 200 mg versus placebo achieved Mayo Clinic Score remission, endoscopic remission and histologic remission. A significantly higher proportion of biologic-experienced patients treated with filgotinib 200mg achieved clinical remission at Week 10 compared with placebo. Patients treated with filgotinib who achieved clinical response or remission at Week 10 were re-randomized to their induction dose of filgotinib or placebo in a 2:1 ratio and treated through Week 58. At Week 58, 37.2 percent of patients receiving filgotinib 200 mg achieved clinical remission, compared with 11.2 percent of patients treated with placebo. A significantly higher proportion of those treated with filgotinib 200 mg versus placebo achieved sustained clinical remission, MCS remission, endoscopic remission and histologic remission. Additionally, a significantly higher proportion of patients treated with filgotinib 200 mg achieved six-month corticosteroid-free clinical remission at Week 58 compared with placebo. Overall, the incidence of adverse events, serious AEs and discontinuations due to AEs were similar in the filgotinib and placebo groups in both the induction and maintenance periods of the study. Serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforation were infrequent and comparable across treatment groups. The most common adverse events of interest in the induction trials were serious infections, herpes zoster, opportunistic infections and pulmonary embolism. In the maintenance trial, the most common adverse events of interest were serious infections, herpes zoster and venous thrombosis. Two deaths were observed in the filgotinib 200 mg treatment group in the maintenance trial; both adverse events leading to deaths were considered by the study investigators to be unrelated to study drug. Gilead
Galapagos
|
|
---|
Hot Stocks
|
Smart for Life Inc trading halted, news pending
19:50
04/19/24
04/19
19:50
04/19/2419:50
SMFL
Smart for Life
|
Hot Stocks
|
Windtree Therapeutics Inc trading halted, news pending
19:50
04/19/24
04/19
19:50
04/19/2419:50
WINT
Windtree Therapeutics
|
Hot Stocks
|
Portland General Electric raises quarterly dividend 5.3% to 50c per share »
18:04
04/19/24
04/19
18:04
04/19/2418:04
POR
Portland General Electric
On April 19, the board of… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
NovaBay receives NYSE American notice of non-compliance »
18:01
04/19/24
04/19
18:01
04/19/2418:01
NBY
NovaBay
NovaBay Pharmaceuticals… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Oragenics announces NYSE American noncompliance notification »
17:53
04/19/24
04/19
17:53
04/19/2417:53
OGEN
Oragenics
Oragenics announced that… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Wrap Technologies receives noncompliance notification from Nasdaq »
17:30
04/19/24
04/19
17:30
04/19/2417:30
WRAP
Wrap Technologies
Wrap Technologies… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
HII awarded $120.3M Navy contract modification »
17:25
04/19/24
04/19
17:25
04/19/2417:25
HII
HII
HII was awarded a $120.3M… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Arista Networks COO Anshul Sadana to resign, effective May 21 »
17:19
04/19/24
04/19
17:19
04/19/2417:19
ANET
Arista Networks
In a regulatory filing,… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Syndicate
|
InnSuites Hospitality Trust files to sell 1M shares of common stock
17:16
04/19/24
04/19
17:16
04/19/2417:16
IHT
InnSuites Hospitality Trust
|
Syndicate
|
Inhibikase Therapeutics files to sell common stock, warrants, no amount given »
17:16
04/19/24
04/19
17:16
04/19/2417:16
IKT
Inhibikase Therapeutics
Maxim Group is acting as… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Aslan Pharmaceuticals receives Nasdaq notice »
17:13
04/19/24
04/19
17:13
04/19/2417:13
ASLN
Aslan Pharmaceuticals
Aslan Pharmaceuticals… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Syndicate
|
Zai Lab files automatic ordinary shares offering
17:13
04/19/24
04/19
17:13
04/19/2417:13
ZLAB
Zai Lab
|
Syndicate
|
Endra Life Sciences files to sell common stock, warrants, no amount given »
17:12
04/19/24
04/19
17:12
04/19/2417:12
NDRA
Endra Life Sciences
Craig-Hallum is sole… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Hepion Pharmaceuticals falls 42% after wind down of ASCEND-NASH trial »
17:08
04/19/24
04/19
17:08
04/19/2417:08
HEPA
Hepion Pharmaceuticals
In after-hours trading,… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
NLS Pharmaceutics receives staff delisting determination letter from Nasdaq »
17:05
04/19/24
04/19
17:05
04/19/2417:05
NLSP
NLS Pharmaceutics
NLS Pharmaceutics… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Conference/Events
|
Steelcase management to meet with Benchmark »
17:04
04/19/24
04/19
17:04
04/19/2417:04
SCS
Steelcase
Group breakfast at 7:45am… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Syndicate
|
AIM ImmunoTech files to sell 9.98M shares of common stock for holders
17:03
04/19/24
04/19
17:03
04/19/2417:03
AIM
AIM ImmunoTech
|
Hot Stocks
|
Lion Group receives noncompliance notification from Nasdaq »
17:03
04/19/24
04/19
17:03
04/19/2417:03
LGHL
Lion Group
Lion Group announced that… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Syndicate
|
RenovoRx files to sell 6.13M shares of common stock for holders
17:03
04/19/24
04/19
17:03
04/19/2417:03
RNXT
RenovoRx
|
Syndicate
|
Yoshiharu files to sell 237,885 shares of Class A common stock for holders
17:02
04/19/24
04/19
17:02
04/19/2417:02
YOSH
Yoshiharu
|
Hot Stocks
|
Hepion Pharmaceuticals trading resumes
17:00
04/19/24
04/19
17:00
04/19/2417:00
HEPA
Hepion Pharmaceuticals
|
General news
|
Treasury Market Summary: »
16:55
04/19/24
04/19
16:55
04/19/2416:55
$ECON
Economic Data
Treasury Market Summary:… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Conference/Events
|
Oppenheimer healthcare analysts hold an analyst/industry conference callssssssss »
16:51
04/19/24
04/19
16:51
04/19/2416:51
Healthcare Analysts,… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Asbury Automotive chief legal officer George Villasana to retire »
16:40
04/19/24
04/19
16:40
04/19/2416:40
ABG
Asbury Automotive
Asbury Automotive… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Conference/Events
|
Editas Medicine management to meet with Oppenheimer »
16:36
04/19/24
04/19
16:36
04/19/2416:36
EDIT
Editas Medicine
Meeting to be held on… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |